ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Olaratumab (IMC-3G3) in Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01204710
Recruitment Status : Completed
First Posted : September 17, 2010
Results First Posted : November 2, 2018
Last Update Posted : November 2, 2018
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company

Brief Summary:
This is a study evaluating the safety and efficacy of the monoclonal antibody olaratumab plus mitoxantrone plus prednisone compared to mitoxantrone plus prednisone in metastatic castration-refractory prostate cancer following disease progression or intolerance on docetaxel-based chemotherapy.

Condition or disease Intervention/treatment Phase
Prostate Cancer Biological: Olaratumab Drug: Mitoxantrone Drug: Prednisone Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 123 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Phase 2 Study of Human Anti-PDGFRα Monoclonal Antibody IMC-3G3 Plus Mitoxantrone Plus Prednisone or Mitoxantrone Plus Prednisone in Metastatic Castration-Refractory Prostate Cancer Following Disease Progression or Intolerance on Docetaxel-based Chemotherapy
Study Start Date : October 2010
Actual Primary Completion Date : September 2012
Actual Study Completion Date : October 2013

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Olaratumab + Mitoxantrone
1 cycle = 3 weeks (21 days)
Biological: Olaratumab
15 milligrams per kilogram (mg/kg) intravenous (IV) Days 1 and 8
Other Names:
  • IMC-3G3
  • LY3012207

Drug: Mitoxantrone

Mitoxantrone 12 milligrams per square meter (mg/m²) IV Day 1

Mitoxantrone is to be administered for up to 12 cycles (total cumulative dose of mitoxantrone is restricted to ≤144 mg/m²)


Drug: Prednisone
5 mg orally (PO) twice daily (BID) on each day

Active Comparator: Mitoxantrone: Optional Olaratumab Monotherapy

1 cycle = 3 weeks (21 days)

Participants who experience progressive disease (PD) have the option to receive olaratumab monotherapy treatment.

Drug: Mitoxantrone

Mitoxantrone 12 milligrams per square meter (mg/m²) IV Day 1

Mitoxantrone is to be administered for up to 12 cycles (total cumulative dose of mitoxantrone is restricted to ≤144 mg/m²)


Drug: Prednisone
5 mg orally (PO) twice daily (BID) on each day




Primary Outcome Measures :
  1. Progression-Free Survival (PFS) [ Time Frame: Randomization to Measured PD or Death Due to Any Cause Up to 23 Months ]
    PFS is measured from randomization to the earliest date of the following events: PD according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version (v) 1.1, is a ≥20% increase in the sum of diameter of the target lesions taking as reference the smallest sum on study and an absolute increase in the sum diameter of ≥5 millimeter (mm), the appearance of 1 or more new lesions and/or unequivocal progression of existing nontarget lesions, unequivocal evidence of progression by bone scan, clinical progression or death from any cause. For participants who had no documented PD or death or had started new anti-cancer therapy or were lost to follow-up, PFS was censored at their last tumor assessment.


Secondary Outcome Measures :
  1. Overall Survival (OS) [ Time Frame: Randomization to Death Due to Any Cause Up to 36 Months ]
    OS was defined as the time from the date of randomization to the date of death from any cause. If the participants were alive at the end of the follow-up period or were lost to follow-up, OS time was censored on the last date the participant was known to be alive.

  2. Percentage of Participants Who Achieved a Best Overall Response of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)] [ Time Frame: Randomization to Objective PD or Death Up to 23 Months ]
    Best response is categorized using the RECIST v1.1 guidelines. CR is the disappearance of all non-nodal target lesions, with the short axes of any target lymph nodes reduced to <10 mm. PR is a ≥30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph nodes), taking as reference the pretreatment sum diameter. Percentage of participants = (number of participants who had CR or PR) / (number of participants treated) * 100.

  3. Percentage of Participants With a ≥50% Decrease in Prostate Specific Androgen (PSA) From Pretreatment to Any Time [ Time Frame: Pretreatment to PD Up to 23 Months ]
    Decrease in PSA ≥50% from pretreatment required confirmation no less than 3 weeks after the initial suggestion of response and occurring prior to documentation of PD. Percentage of participants = (number of participants who had ≥50% decrease in PSA at any time) / (number of participants treated) * 100.

  4. Percentage of Participants With a ≥30% Decrease in PSA From Pretreatment to Week 12 [ Time Frame: Pretreatment through Week 12 ]
    Percentage of participants = (number of participants who had ≥30% decrease in PSA at Week 12) / (number of participants treated) * 100.

  5. Summary Listing of Participants Reporting Treatment-Emergent Adverse Events (TEAE) [ Time Frame: From Start of Treatment Through Study Completion Up to 36 months ]
    Data presented are the number of participants who experienced serious adverse events (SAEs) and other nonserious adverse events (AEs). For participants in mitoxantrone group who had PD and chose optional IMC-3G3 follow-on treatment, the baseline was defined as the last assessment prior to the start of the olaratumab treatment. A summary of SAEs and other nonserious AEs, regardless of causality, is located in the Reported Adverse Events section.

  6. PFS Based on Baseline Circulating Tumor Cells (CTC) Counts [ Time Frame: Randomization to Measured PD or Death Due to Any Cause Up to 23 Months ]
    High expression (HE) of CTC was defined as having CTC counts ≥5 cells/7.5 milliliter (mL) and low expression (LE) of CTC was defined as having CTC counts <5 cells/7.5 mL. PFS is measured from randomization to the earliest date of the following events: PD according to RECIST criteria v. 1.1, is a ≥20% increase in the sum diameter of the target lesions taking as reference the smallest sum on study and an absolute increase in the sum diameter of ≥5 mm, the appearance of 1 or more new lesions and/or unequivocal progression of existing nontarget lesions, unequivocal evidence of progression by bone scan, clinical progression or death from any cause.

  7. OS Based on Baseline CTC Counts [ Time Frame: Randomization to Death Due to Any Cause Up to 36 Months ]
    HE of CTC was defined as having CTC counts ≥5 cells/7.5 mL and LE of CTC was defined as having CTC counts <5 cells/7.5 mL. OS was defined as the time from the date of randomization to the date of death from any cause.

  8. Number of Participants With Negative Platelet-Derived Growth Factor Receptor Alpha (PDGFRα) Protein Expression by Immunohistochemistry (IHC) [ Time Frame: Baseline ]
    PDGFRα protein expression (pretreatment) by IHC was assessed in tumor cells, and was provided as a dichotomous variable with "positive" and "negative" expression. "Positive" corresponds to weak intensity membranous staining comprising greater than 30% of the tumor and/or moderate to strong intensity membranous staining comprising greater than 5% of the tumor. "Negative" corresponds to staining that does not meet these requirements.

  9. Percentage of Participants With Anti-Olaratumab Antibody Assessment (Immunogenicity) [ Time Frame: From Start of Treatment up to 9 Months ]
    Participants with Treatment Emergent (TE) anti-olaratumab antibodies were participants with a 4-fold increase (2 dilutions) increase over a positive baseline antibody titer or for a negative baseline titer, a participant with an increase from the baseline to a level of 1:20.

  10. Maximum Concentration (Cmax) of Olaratumab Cycles 1, 2 and 3 [ Time Frame: Day 1 of Cycles 1, 2 and 3, and Day 8 of Cycles 1 and 3 (21-day cycle) ]

Other Outcome Measures:
  1. Number of Participants Who Died During Study [ Time Frame: From Start of Treatment through Study Completion up to 36 Months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • histologically-confirmed adenocarcinoma of the prostate
  • radiographic evidence of metastatic prostate cancer (Stage M1 or D2)
  • has prostate cancer unresponsive or refractory to medical or surgical castration with a serum testosterone level of <50 nanograms per milliliter (ng/mL)
  • has had disease progression or intolerance on docetaxel-based therapy
  • prostate-specific antigen (PSA) ≥10 ng/mL
  • all clinically significant toxic effects of prior surgery, radiotherapy, chemotherapy or hormonal therapy have resolved to ≤Grade 1, based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version (v) 4.02
  • participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
  • adequate hematologic function
  • adequate hepatic function
  • adequate renal function
  • urinary protein is ≤1 on dipstick or routine analysis
  • life expectancy of more than 3 months
  • fertile man with partners that are women of childbearing potential must use an adequate method of contraception during the study
  • signed Informed Consent Document

Exclusion Criteria:

  • concurrent active malignancy other than adequately treated nonmelanomatous skin cancer or other noninvasive or in situ neoplasms
  • The participant has received more than 1 prior cytotoxic chemotherapy regimen for metastatic disease
  • prior therapy with mitoxantrone for advanced prostate cancer
  • The participant has a history of symptomatic congestive heart failure or has a pre study echocardiogram or multigated acquisition scan with left ventricular ejection fraction that is ≥10% below the lower limit of normal institutional range
  • history of prior treatment with other agents that directly inhibit platelet-derived growth factor (PDGF) or platelet-derived growth factor receptors (PDGFR)
  • known allergy to any of the treatment components: olaratumab, mitoxantrone, and/or prednisone
  • radiotherapy within 21 days prior to first dose of olaratumab
  • any investigational therapy within 30 days of randomization
  • is receiving corticosteroids at a dose >5 mg prednisone PO BID or equivalent
  • received prior strontium-89, rhenium-186, rhenium-188, or samarium-153 radionucleotide therapy and has either ongoing evidence of bone marrow dysfunction or poorly controlled bone pain
  • has any ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, serious cardiac arrhythmia, psychiatric illness, active bleeding or pathological condition that carries a high risk of bleeding, or any other serious uncontrolled medical disorders
  • known or suspected brain or leptomeningeal metastases
  • known human immunodeficiency virus infection or acquired immunodeficiency syndrome-related illness

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01204710


  Show 40 Study Locations
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company

Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT01204710     History of Changes
Other Study ID Numbers: 13938
I5B-IE-JGDD ( Other Identifier: Eli Lilly and Company )
CP15-0805 ( Other Identifier: ImClone Systems )
2009-018015-11 ( EudraCT Number )
First Posted: September 17, 2010    Key Record Dates
Results First Posted: November 2, 2018
Last Update Posted: November 2, 2018
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.

This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.


Keywords provided by Eli Lilly and Company:
Prostate Cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Prednisone
Olaratumab
Mitoxantrone
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action